Mainz Biomed B.V. (MYNZ)
NASDAQ: MYNZ
· Real-Time Price · USD
2.85
-0.13 (-4.36%)
At close: May 02, 2025, 3:59 PM
2.94
3.16%
After-hours: May 02, 2025, 07:54 PM EDT
-4.36% (1D)
| Bid | 2.94 |
| Market Cap | 8.66M |
| Revenue (ttm) | 735.53K |
| Net Income (ttm) | -16.21M |
| EPS (ttm) | -21.62 |
| PE Ratio (ttm) | -0.13 |
| Forward PE | -1.6 |
| Analyst | Hold |
| Ask | 3.28 |
| Volume | 295,119 |
| Avg. Volume (20D) | 268,958 |
| Open | 3.07 |
| Previous Close | 2.98 |
| Day's Range | 2.83 - 3.07 |
| 52-Week Range | 0.18 - 8.20 |
| Beta | 0.53 |
About MYNZ
Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and...
Industry Medical - Diagnostics & Research
Sector Healthcare
IPO Date Nov 5, 2021
Employees 19
Stock Exchange NASDAQ
Ticker Symbol MYNZ
Website https://mainzbiomed.com
Analyst Forecast
According to 2 analyst ratings, the average rating for MYNZ stock is "Hold." The 12-month stock price forecast is $14, which is an increase of 391.23% from the latest price.
Stock ForecastsNext Earnings Release
Mainz Biomed B.V. is scheduled to release its earnings on May 16, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 week ago
+4.82%
Mainz Biomed shares are trading higher after the c...
Unlock content with
Pro Subscription
1 month ago
+17.41%
Mainz Biomed shares are trading higher on possible continued strength after the company reported a year-over-year increase in FY24 EPS results on Tuesday.
